The European Medicines Agency (EMA) has rejected a licence for an Alzheimer's treatment which slows cognitive decline. The EMA said the benefits of lecanemab did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain.

https://www.ft.com/content/27eafb84-f8b0-428a...8e66ef8961

https://www.alzheimers.org.uk/news/2024-07-26...-lecanemab